<H1>Chapter DOI: 10.1007/978-1-60327-829-4_30<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>27</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>26</td></tr><tr><td>BibStructured Count</td><td width="10%">25</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>21</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_30</td><td>BibArticle</td><td>Frauwirth KA, Thompson, CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109(3):295&#8211;9.</td><td><a href=http://dx.doi.org/10.1172/JCI0214941>10.1172/JCI0214941</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Author_FamilyName_1, VolumeID, FirstPage, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR2_30</td><td>BibArticle</td><td>Chambers C, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565&#8211;94.</td><td><a href=http://dx.doi.org/10.1146/annurev.immunol.19.1.565>10.1146/annurev.immunol.19.1.565</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_30</td><td>BibArticle</td><td>Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4(5):336&#8211;47.</td><td><a href=http://dx.doi.org/10.1038/nri1349>10.1038/nri1349</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_30</td><td>BibArticle</td><td>Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 2006;24(5):442&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2005.08.011>10.1016/j.urolonc.2005.08.011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_30</td><td>BibArticle</td><td>Waterhouse P, Penninger JM, Timms E, Wakeham A. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270(5238):985&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.270.5238.985>10.1126/science.270.5238.985</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_30</td><td>BibArticle</td><td>Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3(5):541&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/1074-7613(95)90125-6>10.1016/1074-7613(95)90125-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_30</td><td>BibArticle</td><td>Mandelbrot DA, McAdam AJ, Sharpe AH. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 1999;189(2):435&#8211;40.</td><td><a href=http://dx.doi.org/10.1084/jem.189.2.435>10.1084/jem.189.2.435</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_30</td><td>BibArticle</td><td>Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997;94(15):8099&#8211;103.</td><td><a href=http://dx.doi.org/10.1073/pnas.94.15.8099>10.1073/pnas.94.15.8099</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_30</td><td>BibArticle</td><td>Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999;96(26):15074&#8211;9.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.26.15074>10.1073/pnas.96.26.15074</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_30</td><td>BibArticle</td><td>Small EJ, Tchekmedyian NS, Rini B, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810&#8211;5.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-2318>10.1158/1078-0432.CCR-06-2318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_30</td><td>BibArticle</td><td>Hurwitz AA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60(9):2444&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12_30</td><td>BibArticle</td><td>Fong L, et al. Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007;25(18S):3001.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_30</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gerritsen</span> <span style='background:#DDDDDD'>W</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>van den</span> <span style='background:#BCBCBC'>Eertwegh</span> <span style='background:#DDDDDD'>AJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>T.</span> <span style='background:#FFFF80'>de</span> <span style='background:#BCBCBC'>Gruijl T</span></span>, et al.</aug> Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). Proc Am Soc Clin Oncol 2008:Abstr <span style='background:#66FF66'>5146</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_30</td><td>BibArticle</td><td>Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8(19):1765&#8211;80.</td><td><a href=http://dx.doi.org/10.2174/1381612023394089>10.2174/1381612023394089</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_30</td><td>BibArticle</td><td>Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953;26(305):234&#8211;41.</td><td><a href=http://dx.doi.org/10.1259/0007-1285-26-305-234>10.1259/0007-1285-26-305-234</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_30</td><td>BibArticle</td><td>Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58(3):862&#8211;70.</td><td><a href=http://dx.doi.org/10.1016/j.ijrobp.2003.09.012>10.1016/j.ijrobp.2003.09.012</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_30</td><td>BibArticle</td><td>Demaria S, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11(2 Pt 1):728&#8211;34.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_30</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Beer</span> <span style='background:#DDDDDD'>TM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Slovin</span> <span style='background:#DDDDDD'>SF</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Higano</span> <span style='background:#DDDDDD'>CS</span></span>, et al.</aug> Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol 2008:Abstr <span style='background:#66FF66'>5004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_30</td><td>BibArticle</td><td>Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23(25):6043&#8211;53.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.06.205>10.1200/JCO.2005.06.205</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_30</td><td>BibArticle</td><td>Fasso M, Waitz R, Hou Y, et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A 2008;105(9):3509&#8211;14.</td><td><a href=http://dx.doi.org/10.1073/pnas.0712269105>10.1073/pnas.0712269105</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_30</td><td>BibArticle</td><td>Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67(18):8900&#8211;5.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-1866>10.1158/0008-5472.CAN-07-1866</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_30</td><td>BibArticle</td><td>Imai H, Saio M, Nonaka K, et al. Depletion of CD4+ CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007;98(3):416&#8211;23.</td><td><a href=http://dx.doi.org/10.1111/j.1349-7006.2006.00385.x>10.1111/j.1349-7006.2006.00385.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_30</td><td>BibArticle</td><td>Tuve S, Chen B-M, Liu Y, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007;67(12):5929&#8211;39.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-4296>10.1158/0008-5472.CAN-06-4296</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_30</td><td>BibArticle</td><td>Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112(3):610&#8211;8.</td><td><a href=http://dx.doi.org/10.1182/blood-2008-01-135319>10.1182/blood-2008-01-135319</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_30</td><td>BibArticle</td><td>Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623&#8211;33.</td><td><a href=http://dx.doi.org/10.1172/JCI25947>10.1172/JCI25947</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_30</td><td>BibArticle</td><td>Ghiringhelli F, Menard C, PE Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641&#8211;8.</td><td><a href=http://dx.doi.org/10.1007/s00262-006-0225-8>10.1007/s00262-006-0225-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_30</td><td>BibArticle</td><td>Kavanagh B, O&#8217;Brien S, Lee D, et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008;112(4):1175&#8211;83.</td><td><a href=http://dx.doi.org/10.1182/blood-2007-11-125435>10.1182/blood-2007-11-125435</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>